[Moderate hypofractionated radiotherapy for bladder cancer-a new standard of care?]

[Article in German]

Affiliations

Comment

[Article in German]

Oliver J Ott. Strahlenther Onkol. 2021 Sep.

. 2021 Sep;197(9):854-856.

doi: 10.1007/s00066-021-01804-2. Epub 2021 Jul 6.

¹ Strahlenklinik, Universitätsklinikum Erlangen, Universitätsstr. 27, 91054, Erlangen, Deutschland. oliver.ott@uk-erlangen.de.

No abstract available

Comment on

Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
Choudhury A, Porta N, Hall E, Song YP, Owen R, MacKay R, West CML, Lewis R, Hussain SA, James ND, Huddart R, Hoskin P; BC2001 and BCON investigators. Choudhury A, et al. Lancet Oncol. 2021 Feb;22(2):246-255. doi: 10.1016/S1470-2045(20)30607-0. Lancet Oncol. 2021. PMID: 33539743 Free PMC article.

1. Choudhury A, Porta N, Hall E, et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021;22:246–255. doi: 10.1016/S1470-2045(20)30607-0. - DOI - PMC - PubMed
1. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477–1488. doi: 10.1056/NEJMoa1106106. - DOI - PubMed
1. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. 2010;28:4912–4918. doi: 10.1200/JCO.2010.28.4950. - DOI - PubMed
1. Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66:120–137. doi: 10.1016/j.eururo.2014.02.038. - DOI - PubMed
1. Rödel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061–3071. doi: 10.1200/JCO.2002.11.027. - DOI - PubMed